StreetAlpha.app
Home › Stocks › NRIX

Nurix Therapeutics, Inc. (NRIX)

$12.85
▼ −5.51%
LAST CLOSE · NOV 20

Nurix is a Brisbane, California biopharmaceutical company developing cancer and inflammation drugs that remove disease-causing proteins. It last closed at $12.85 on Nov 20, down 5.51% on the day. The next earnings report for NRIX is expected around Wed, Jan 27, 2027, after the close. For the quarter ended Aug 2026, NRIX reported EPS of $4.73 on revenue of $673.1M, with revenue up 8426.3% from a year ago. Over its last 8 reports the stock moved an average of 4.3% the session after earnings. Over the last 12 months NRIX insiders bought $0 of stock on the open market and sold $5.8M, according to SEC Form 4 filings.

AI Auto Pilots
Is NRIX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold NRIX.

Key Stats

Last 12 months
Results
Revenue
$701.9M
+738.8% vs a year ago
Net income
$294.9M
42.0% margin
EPS (diluted)
$2.43
Free cash flow
$369.8M
52.7% margin
Valuation
Market cap
$1.4B
109.2M shares
P/E
5.3
Price over 12 month EPS
Price to sales
2.0
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$720.2M
At Aug 31
Shareholder equity
$968.3M
Shares outstanding
109.2M
At Sep 30
Fiscal year endsNovember
ExchangeNasdaq
Financials history
FY2021: $29.8M$29.8MFY2021FY2022: $38.6M$38.6MFY2022FY2023: $77.0M$77.0MFY2023FY2024: $54.5M$54.5MFY2024FY2025: $84.0M$84.0MFY2025

From NRIX's SEC filings, latest 10-Q for the period ending Aug 31, 2026 (filed Oct 13). Last 12 months adds up the four latest quarters.

Next report
Jan 27
Estimated date · After the close
Reported EPS
$4.73
Quarter ended Aug 2026
Year ago EPS
-$1.03
Same quarter last year
Revenue
$673.1M
+8426.3% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Nov 2024: -$0.75Nov '24Feb 2025: -$0.67Feb '25May 2025: -$0.52May '25Aug 2025: -$1.03Aug '25Nov 2025: -$0.83Nov '25Feb 2026: -$0.79Feb '26May 2026: -$0.81May '26Aug 2026: $4.73Aug '26Latest $4.73
Revenue by quarter
Nov 2024: $13.3MNov '24Feb 2025: $18.5MFeb '25May 2025: $44.1MMay '25Aug 2025: $7.9MAug '25Nov 2025: $13.6MNov '25Feb 2026: $6.3MFeb '26May 2026: $9.0MMay '26Aug 2026: $673.1MAug '26Latest $673.1M
How NRIX moved after its last 8 reports
Average move the session after a report ±4.3%
Oct 13, 2026Time not announced−0.1%
Jul 9, 2026After the close−6.6%
Apr 8, 2026Time not announced−4.6%
Jan 28, 2026After the close−1.6%
Oct 9, 2025After the close−10.1%
Jul 9, 2025After the close−3.9%
Apr 8, 2025After the close+3.7%
Jan 13, 2025Time not announced+4.2%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on NRIXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on NRIX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on NRIX

Technical Analysis

NRIX · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 48% below its 20 day and 72% below its 50 day average. It is 56% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 21), oversold. The nearest support is the 52 week low at $12.82, and the nearest resistance the Pivot at $13.12.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 10.3%/day
Key levels
$28.2352 week high+119.7%
$23.56100 day average+83.3%
$22.0750 day average+71.8%
$20.06200 day average+56.1%
$19.0020 day average+47.9%
$16.76Swing high (Nov 10)+30.4%
$13.41Pivot R1+4.4%
$13.12Pivot+2.1%
$12.85Last close
$12.8252 week low−0.2%
$12.56Pivot S1−2.3%
Indicators
RSI (14)21.23Oversold below 30Oversold
MACD-2.85Below its signal lineBearish
Stochastic1.3Near the bottom of its rangeOversold
ADX (14)41.6Strong downtrend
Williams %R-99.8Oversold below −80, overbought above −20Oversold
CCI (20)-77.9Oversold below −100, overbought above 100Neutral
Rate of change−16.0%Change over 10 sessionsBearish
ATR (14)$1.32Typical daily range, 10.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for NRIX

What happened before

See how NRIX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow NRIX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How NRIX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for NRIXHow many large options trades hit NRIX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

NRIX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲124 buying vs 83 selling
  • ▲Held by funds +2.2 pts
  • ▲Funds holding +22
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding234212+10.4%
In funds' top 1076+16.7%
Held by funds109.6%107.4%+2.2 pts
New / increased44 / 8044 / 68+10.7%
Reduced / sold out60 / 2363 / 27−7.8%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See NRIX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

NRIX Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$5.8M36 sales · 4 insiders
77% of the selling was under pre-arranged trading plans.
2025-12 sold $67K2026-01 sold $285K2026-02 sold $238K2026-03 sold $126K2026-04 sold $271K2026-05 sold $462K2026-06 sold $824K2026-07 sold $506K2026-08 sold $707K2026-09 sold $186K2026-10 sold $877K2026-11 sold $649KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 4Houte Hans vanCFOSale plan4,769$15.63$75K
Nov 3Christine RingChief Legal OfficerSale plan16,715$25.84$432K
Nov 2Gwenn HansenChief Scientific OfficerSale plan5,409$26.42$143K
Oct 30Christine RingChief Legal OfficerSale3,957$26.28$104K
Oct 30Houte Hans vanCFOSale2,834$26.28$74K
Oct 15Gwenn HansenChief Scientific OfficerSale plan1,452$25.00$36K
Every insider buy and sale for NRIX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See NRIX insider trades →

From SEC Form 4 filings by NRIX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NRIX is in one of them and how their past NRIX trades turned out.

NRIX in the AI portfolios
Loading…

NRIX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered NRIX in an article yet. Here's the latest on the wider market.

NRIX in the news

About Nurix Therapeutics

Nurix is a clinical stage biopharmaceutical company based in Brisbane, California. It develops medicines based on targeted protein degradation, a approach that removes disease-causing proteins, with a focus on cancer and inflammatory conditions. Its lead candidate, bexobrutideg, is being studied in patients with relapsed or refractory chronic lymphocytic leukemia. The company also works with large drug makers, including Gilead, Sanofi and Pfizer, on collaborations that use its platform, which combines DNA encoded libraries with artificial intelligence, to find new drug candidates.

Headquarters
Brisbane, CA
Founded
2012